An interventional study of Cleanweb electronic messaging ePro and Usual follow-up in Gout, Inflammatory Rheumatism and Hyperuricemia, sponsored by Assistance Publique - Hôpitaux de Paris. Active, not recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
Among 18 studies in Gout with a site in France — 5 open to participants now, 8 under way, 1 of them phase 3. Gout · France.
Among the 18 studies in Gout with a site in France, this one is the 4th largest by planned enrollment of the 11 interventional ones, is one of 2 that started in 2021, is one of 5 with no phase, and was the 10th registered.
345 studies on the registry are indexed under Gout; 49 are open to participants now.
This study's planned enrollment of 204 is above the median of 83 across 286 interventional studies indexed under Gout.
Browse Gout studies →5 of the 18 studies in Gout with a site in France are open now, in 5 countries. Each count lists the studies.
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; 0 take children under 18; 0 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →18 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2021.
Median enrollment 200 across the 11 interventional studies, 240 across the 7 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
3 of 18 have an industry lead sponsor. The 9 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 9 studies filed under Gout — fewer than ten, so there is no comparison to draw.
2 of the studies in Gout with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT05927688University Hospital, Strasbourg, FranceAssessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments | 2027-07 |
Among the 18 studies in Gout with a site in France, from their registry updates:
Gout is secondary to urate crystal deposition after chronic elevation of serum urate level (SUL). Long-term lowering SUL below 360 µmol/L allows dissolution of deposited crystals and disease cure. There is currently a paradoxical observation: while urate-lowering therapy (ULT) is available and efficient there is an increase of gout prevalence and severity. The apparent failure of ULT in gout management is due to several causes including unadjusted dosage, no SUL verification, irregular follow-up and low treatment compliance.
In contrast, a nurse-led treat-to-target (T2T) strategy with regular adaptations of ULT until reaching SUL target allows gout cure in more than 90% of patients. We hypothesize that an electronic messaging-led T2T strategy will allow obtaining similar results.
The aim of this study is to demonstrate that email-led T2T strategy during ULT is superior to usual care.
The study will include 204 gouty patients without ULT or with ineffective ULT. This is a multicenter and randomized study (e-mail follow-up vs usual follow-up groups).
This study will include the following visits:
Selection/inclusion visit (V0):
The study ends after the M12 consultation. The total duration of participation in the study is 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Man (2 pts) Previous crisis (2 pts) Involvement of first metatarsophalangeal joint (MTP1) (2.5 pts) Maximum pain within 24 hours (0.5pt) Redness (1 pt) HTA or cardiovascular disease (1.5 pts) SUL > 360 μmol/l during the crisis (3.5 pts)
Exclusion Criteria:
Email-led treat-to-target strategy with regular adaptation of ULT via electronic messaging
Other: Cleanweb electronic messaging ePro
Adaptation and follow-up of ULT according to referring physician's habits
Other: Usual follow-up
Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
Adaptation and follow-up of ULT according to referring physician's habits
Proportion of patients with target SUL (<360 μmol /L or <300 μmol /L in tophaceous gout)
Time frame: Month 12
Average dose of ULT (allopurinol and febuxostat)
Time frame: Month 12
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Apr 2026, 52 months after the start.
Of 34 non-industry interventional studies with no phase under Gout, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 52 months is above that.
Counting every sponsor, half of 35 studies reached it within 29 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →